The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study.
Dopamine
epidemiology
ethnicity
migration
psychosis
race
schizophrenia
stress
Journal
Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
pubmed:
23
9
2020
medline:
3
6
2022
entrez:
22
9
2020
Statut:
ppublish
Résumé
In Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: 'minorities'). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population). The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of Diseases, 10th edition, codes F20-F33) from 13 sites. The standardized incidence rates for minorities, combined into one category, varied from 12.2 in Valencia to 82.5 per 100 000 in Paris. These rates were generally high at sites with high rates for the reference population, and low at sites with low rates for the reference population. IRRs for minorities (combined into one category) varied from 0.70 (95% CI 0.32-1.53) in Valencia to 2.47 (95% CI 1.66-3.69) in Paris (test for interaction: p = 0.031). At most sites, IRRs were higher for persons from non-Western countries than for those from Western countries, with the highest IRRs for individuals from sub-Saharan Africa (adjusted IRR = 3.23, 95% CI 2.66-3.93). Incidence rates vary by region of origin, region of destination and their combination. This suggests that they are strongly influenced by the social context.
Sections du résumé
BACKGROUND
In Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: 'minorities'). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population).
METHODS
The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of Diseases, 10th edition, codes F20-F33) from 13 sites.
RESULTS
The standardized incidence rates for minorities, combined into one category, varied from 12.2 in Valencia to 82.5 per 100 000 in Paris. These rates were generally high at sites with high rates for the reference population, and low at sites with low rates for the reference population. IRRs for minorities (combined into one category) varied from 0.70 (95% CI 0.32-1.53) in Valencia to 2.47 (95% CI 1.66-3.69) in Paris (test for interaction: p = 0.031). At most sites, IRRs were higher for persons from non-Western countries than for those from Western countries, with the highest IRRs for individuals from sub-Saharan Africa (adjusted IRR = 3.23, 95% CI 2.66-3.93).
CONCLUSIONS
Incidence rates vary by region of origin, region of destination and their combination. This suggests that they are strongly influenced by the social context.
Identifiants
pubmed: 32958094
doi: 10.1017/S0033291720003219
pii: S0033291720003219
pmc: PMC9157293
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1376-1385Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101272/Z/13/Z
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Références
Br J Psychiatry. 2005 Jan;186:74-5
pubmed: 15630127
Psychol Med. 2019 Oct;49(14):2354-2363
pubmed: 30514409
Lancet Psychiatry. 2016 Sep;3(9):832-41
pubmed: 27528097
Eur Psychiatry. 2008 Jan;23 Suppl 1:14-20
pubmed: 18371575
J Nerv Ment Dis. 1985 Oct;173(10):577-81
pubmed: 3875685
Schizophr Bull. 2017 Mar 1;43(2):293-301
pubmed: 28057720
Br J Psychiatry. 2011 Aug;199(2):151-5
pubmed: 21804150
Psychol Med. 2021 Jul;51(9):1536-1548
pubmed: 32122439
Schizophr Bull. 2017 Jan 3;43(2):287-292
pubmed: 28053019
JAMA Psychiatry. 2018 Jan 1;75(1):36-46
pubmed: 29214289
JAMA Psychiatry. 2014 Dec 1;71(12):1364-72
pubmed: 25271822
Schizophr Bull. 2013 Nov;39(6):1180-6
pubmed: 24062592
Lancet Public Health. 2019 May;4(5):e229-e244
pubmed: 31054641
Br J Psychiatry. 1996 Nov;169(5):587-92
pubmed: 8932887
Psychol Med. 2011 May;41(5):897-910
pubmed: 20663257
Psychol Med. 2020 Jan;50(2):303-313
pubmed: 30722795
Soc Psychiatry Psychiatr Epidemiol. 2014 Jul;49(7):1161-74
pubmed: 24213521
World Psychiatry. 2019 Oct;18(3):247-258
pubmed: 31496097
Am J Psychiatry. 2005 Jan;162(1):12-24
pubmed: 15625195
Schizophr Res. 2002 Apr 1;54(3):219-21
pubmed: 11950546
Am J Psychiatry. 2017 Feb 1;174(2):143-153
pubmed: 27771972
Soc Psychiatry Psychiatr Epidemiol. 2017 Feb;52(2):147-154
pubmed: 27847980
Br J Psychiatry. 2005 Aug;187:101-2
pubmed: 16055818
Br J Psychiatry. 1999 Jul;175:28-33
pubmed: 10621765
Br J Psychiatry. 1995 Aug;167(2):193-6
pubmed: 7582668